Company Filing History:
Years Active: 2000-2010
Title: **Fruma Yehiely: Pioneering Innovations in Gene Identification**
Introduction
Fruma Yehiely, an accomplished inventor based in Chicago, IL, has made significant contributions to the field of gene identification. With a portfolio that includes two patents, her work aims to enhance our understanding of specific cell phenotypes and their maintenance.
Latest Patents
Yehiely's most notable patent is focused on the therapeutic modulation of the Fas pathway. This innovative method involves identifying genes essential for maintaining specific cell phenotypes. The process starts with identifying a cell type with a particular phenotype. Gene inactivation is performed on samples from these cells. Subsequent selection involves determining which cells maintain their phenotype after gene inactivation, revealing the critical genes responsible for phenotype integrity. The method leads to the identification of essential genes and even includes antibodies targeted against their products. Furthermore, Yehiely has developed a customized kit to facilitate the gene identification process.
Career Highlights
Throughout her career, Fruma has worked with prominent organizations in the biotech field, including Quark Biotech, Inc. and Quark Pharmaceuticals, Inc. Her experience in these companies has bolstered her research and innovation pursuits, underscoring her status as a key player in biotechnological advancements.
Collaborations
Yehiely's innovative journey has been shaped by collaborations with talented individuals in the field. Among her notable coworkers are Paz Einat and Louis Paul Deiss, both of whom have contributed significantly to her research endeavors.
Conclusion
Fruma Yehiely's work represents a vital intersection of innovation and application in the realm of gene research. Her patents reflect a deep commitment to understanding the complexities of cell phenotypes and their genetic underpinnings, contributing to broader advancements in therapeutic applications.